{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:22:21Z","timestamp":1770834141109,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.chest.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T01:51:58Z","timestamp":1566179518000},"page":"1062-1067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis"],"prefix":"10.1016","volume":"156","author":[{"given":"Heng-Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera P.","family":"Krymskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth P.","family":"Henske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2019.08.005_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CLEP.S50780","article-title":"Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis","volume":"7","author":"Taveira-DaSilva","year":"2015","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.chest.2019.08.005_bib2","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.chest.2019.08.005_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/35101031","article-title":"Two genetic hits (more or less) to cancer","volume":"1","author":"Knudson","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.chest.2019.08.005_bib4","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.chest.2019.08.005_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/301804","article-title":"Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis","volume":"62","author":"Smolarek","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.chest.2019.08.005_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.chest.2019.08.005_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jmg.26.8.511","article-title":"Evidence for genetic heterogeneity in tuberous sclerosis","volume":"26","author":"Sampson","year":"1989","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.chest.2019.08.005_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1165\/rcmb.2006-0372TR","article-title":"Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans","volume":"36","author":"Juvet","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"34","key":"10.1016\/j.chest.2019.08.005_bib9","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"Goncharova","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.chest.2019.08.005_bib10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.chest.2019.08.005_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.chest.2019.08.005_bib12","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2019.08.005_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-med-050715-104245","article-title":"Lymphangioleiomyomatosis: a monogenic model of malignancy","volume":"68","author":"Krymskaya","year":"2017","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.chest.2019.08.005_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.chest.2019.08.005_bib15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.chest.2019.08.005_bib16","doi-asserted-by":"crossref","first-page":"e98674","DOI":"10.1172\/jci.insight.98674","article-title":"TSC2-deficient tumors have evidence of T\u00a0cell exhaustion and respond to anti-PD-1\/anti-CTLA-4 immunotherapy","volume":"3","author":"Liu","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.chest.2019.08.005_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2018-0123OC","article-title":"Immune checkpoint ligand PD-L1 is upregulated in pulmonary lymphangioleiomyomatosis","volume":"59","author":"Maisel","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"10.1016\/j.chest.2019.08.005_bib18","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.chest.2019.08.005_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-018-0415-x","article-title":"Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy","volume":"6","author":"Lattanzi","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.chest.2019.08.005_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ajpath.2013.04.002","article-title":"Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis","volume":"183","author":"Gilbert","year":"2013","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.chest.2019.08.005_bib21","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-10-0043","article-title":"Anti-GD3 chimeric sFv-CD28\/T-cell receptor zeta designer T\u00a0cells for treatment of metastatic melanoma and other neuroectodermal tumors","volume":"16","author":"Lo","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.chest.2019.08.005_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.neo.7900108","article-title":"Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors","volume":"2","author":"Yun","year":"2000","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.chest.2019.08.005_bib23","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1183\/09031936.95.08111879","article-title":"Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax","volume":"8","author":"Tanaka","year":"1995","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2019.08.005_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-010-0942-x","article-title":"Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used","volume":"60","author":"Lesterhuis","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1016\/j.chest.2019.08.005_bib25","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2019.08.005_bib26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4049\/jimmunol.182.3.1270","article-title":"Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene","volume":"182","author":"Pacheco-Rodriguez","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"7355","key":"10.1016\/j.chest.2019.08.005_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.chest.2019.08.005_bib28","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2353\/ajpath.2009.090525","article-title":"Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T\u00a0cells","volume":"175","author":"Klarquist","year":"2009","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.chest.2019.08.005_bib29","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.chest.2019.08.005_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87270","article-title":"NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline","volume":"1","author":"Osterburg","year":"2016","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.chest.2019.08.005_bib31","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1172\/JCI61931","article-title":"Suppressing T\u00a0cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects","volume":"122","author":"Ruocco","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.chest.2019.08.005_bib32","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1084\/jem.20041522","article-title":"NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer","volume":"200","author":"Smyth","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.chest.2019.08.005_bib33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2004-11-4365","article-title":"Chimeric NK-receptor-bearing T\u00a0cells mediate antitumor immunotherapy","volume":"106","author":"Zhang","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.chest.2019.08.005_bib34","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1164\/rccm.201205-0848OE","article-title":"Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm","volume":"186","author":"McCormack","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2019.08.005_bib35","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1038\/ncomms15816","article-title":"The genomic landscape of tuberous sclerosis complex","volume":"8","author":"Martin","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.chest.2019.08.005_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.chest.2019.08.005_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.chest.2019.08.005_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369219314618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369219314618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:13:34Z","timestamp":1757924014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369219314618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0012369219314618"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2019.08.005","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}